Otobiotic AB Ear Drop is a combination pharmaceutical formulation containing Ofloxacin 0.3% w/v, a broad-spectrum fluoroquinolone antibiotic, and Dexamethasone 0.1% w/v, a potent corticosteroid. This preparation is indicated for the treatment of bacterial infections of the external auditory canal and middle ear, particularly otitis externa and otitis media with an inflammatory component. Ofloxacin exerts its antibacterial effect by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing bacterial replication and promoting eradication of susceptible pathogens. Dexamethasone provides anti-inflammatory action by suppressing the release of inflammatory mediators, reducing edema, erythema, and pain associated with infection. The combination therapy ensures both effective microbial clearance and symptomatic relief. Otobiotic AB Ear Drop is typically administered topically, allowing for targeted delivery to the site of infection with minimal systemic absorption. It is contraindicated in patients with hypersensitivity to fluoroquinolones, corticosteroids, or any component of the formulation. Care should be taken in cases of tympanic membrane perforation. Use during pregnancy and lactation should be under medical supervision. Common adverse effects may include local irritation, itching, or transient burning sensation. Proper administration technique and adherence to prescribed dosage are essential for optimal therapeutic outcomes.